UA121085U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography. Additionally, serum MTHFR C677T polymorphism, TFR- (1, homocysteine, PSA) and homozygous carrier 677-TT, TFR- levels (1 <14 ng / ml, homocysteine> 20 μmol / l, CPP) are further determined in serum. mg / l diagnose the development of atherosclerosis.

Description

The proposed useful model of the method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography (|Okorokov A.N. Diagnostics of diseases of internal organs. - Vol. 6. - M.: Med. lit., 2003. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of transforming growth factor beta 1 (TGF-VI), homocysteine, C-reactive protein ( SRP), and with homozygous carrier 677-TT, levels of TFR-B1 "14 ng/ml, homocysteine 220 μmol/l, SRP "6 mg/l diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the blood serum of the patient, the MTNEV C677T gene polymorphism is determined. The content is determined by the immunoenzymatic method

TFR-VI, homocysteine, SRP. With homozygous carrier 677-TT, levels of TFR-VI "14 ng/ml, homocysteine 220 μmol/l, SRP "6 mg/l, the development of atherosclerosis is diagnosed.

A specific example of using the method

Patient Kh., 40 years old, hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. The MTNEV gene polymorphism was determined in blood serum

C677T. The content of TFR-DV1, homocysteine, and SRP was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of TFR-DV1-8.6 ng/ml, homocysteine - 28 μmol/l, SRP - 14 mg/l. The development of atherosclerosis was diagnosed. Arteriographic signs of atherosclerosis have been established

Only after 12 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages of the process.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, examination of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by the fact that the blood serum is additionally determined by the polymorphism of the MTNEV C677T gene, the content of TGF-DRI, homocysteine, SRP, and in case of homozygous carrier 677-TT, TFR-DI levels "14 ng/ml, homocysteine 220 μmol/l, SRP »6 mg/l diagnose the development of atherosclerosis.